Alan Marcus
Endocrinology, Diabetes & Metabolism · Laguna Hills, CANPI 1275631657
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (35.6%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Corcept Therapeutics at 58.0% of the total. Reporting peaked in 2019 at $48,761 and has fallen 89.2% since, to $5,243 in 2025. Among endocrinology, diabetes & metabolism clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,917 payments — averaging $61.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$69K
- Mannkind Corporation$16K
- Vertex$6K
- AbbVie$4K
- AstraZeneca$3K
- Novo Nordisk$3K
- plus $18K from 54 others
Across 9 payments — averaging $2988.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$15K
- Corcept Therapeutics$12K
What the payments were for
- Consulting fees$42,16736%
- Speaking & faculty fees$37,95432%
- Travel & lodging$6,3625%
- Food & beverage$31,74527%
- Education$2970%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$118,524 in reported general payments places this provider in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 621 | $632,898 |
| MounjaroTirzepatide | 325 | $395,564 |
| JardianceEmpagliflozin | 248 | $316,812 |
| Repatha SureclickEvolocumab | 155 | $143,329 |
| FarxigaDapagliflozin Propanediol | 106 | $122,526 |
| Norditropin FlexproSomatropin | 17 | $76,117 |
| XyostedTestosterone Enanthate | 51 | $59,847 |
| KerendiaFinerenone | 29 | $53,423 |
| Praluent PenAlirocumab | 70 | $49,902 |
| AfrezzaInsulin Regular, Human | 47 | $45,536 |
| EliquisApixaban | 34 | $44,956 |
| TrulicityDulaglutide | 25 | $35,608 |
| XareltoRivaroxaban | 40 | $30,111 |
| SynthroidLevothyroxine Sodium | 297 | $30,102 |
| VascepaIcosapent Ethyl | 32 | $24,284 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $2,528 | $632,898621 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,850 | $431,173350 claims |
| Boehringer IngelheimJardiance, Tradjenta | $800 | $327,772262 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $2,854 | $135,699125 claims |
| Antares Pharma, Inc.Xyosted | $398 | $59,84751 claims |
| BayerKerendia | $305 | $53,42329 claims |
| AbbVieSynthroid, Linzess | $4,399 | $47,993317 claims |
| Mannkind CorporationAfrezza | $15,581 | $45,53647 claims |
| PfizerEliquis | $241 | $44,95634 claims |
| Johnson & JohnsonXarelto | $622 | $30,11140 claims |
| Axsome Therapeutics, Inc.Sunosi | $234 | $19,65822 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity, Dexilant | $679 | $16,66432 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Laguna Hills
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.